We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery
Read MoreHide Full Article
AMN Healthcare Services, Inc. (AMN - Free Report) launched an innovative technology suite, WorkWise, last Wednesday. The suite is expected to unify the company’s technologies into one single technology offering.
Per AMN Healthcare, WorkWise has been designed to streamline workforce processes by combining the capabilities of quantifying staffing demand with predictive scheduling, automated workforce management and enhanced clinician engagement using AI technology. The technology suite will likely empower healthcare systems to efficiently source the appropriate talent, while effectively managing costs.
The latest launch is expected to significantly boost AMN Healthcare’s Technology and Workforce Solutions business and solidify its foothold in the healthcare space.
Likely Trend of AMN Stock Following the News
Following the announcement on Oct. 2, shares of the company moved nearly 2.8% south to $38.64 at yesterday’s close.
Historically, the company has gained a high level of synergies from its product launches. Although the latest launch is likely to be beneficial for AMN’s top-line growth going forward, the stock declined overall since the announcement despite a slight gain yesterday.
AMN Healthcare currently has a market capitalization of $1.47 billion. It has an earnings yield of 8.3%, higher than the industry’s 3.6%. In the last reported quarter, AMN delivered an earnings surprise of 30.7%.
Significance of the Launch of AMN Healthcare’s WorkWise
Per AMN Healthcare, WorkWise is completely integrated with healthcare organizations’ internal systems. This is expected to enable hospitals to optimize personnel for any type of job (permanent, per diem, contract), sourcing from internal and external talent, to reduce costs and predict staffing needs with greater precision. The solution will likely leverage automation and data analysis to provide insights and build engaged talent networks for effective workforce management and increased speed-to-fill for staffing needs.
AMN Healthcare’s management believes that WorkWise will be an integrated solution with multiple capabilities that can work together to address complex workforce challenges in the healthcare industry. It is expected to provide a full end-to-end solution for hospitals and healthcare systems, which is built to adapt and evolve with their needs.
Industry Prospects in Favor of AMN
Per a report by Grand View Research, the global healthcare workforce management system market was valued at $1.9 billion in 2023 and is anticipated to witness a CAGR of 13.2% between 2024 and 2030. Factors like the shift toward value-based reimbursements and the increasing adoption of telehealth technologies and AI-driven analytics are likely to drive the market.
Given the market potential, the latest launch will likely provide a significant impetus to AMN Healthcare’s business.
AMN Healthcare’s Notable Launches
In August, AMN Healthcare launched Strategic Partnership Solutions. It aims to transform language access programs in healthcare organizations by providing comprehensive language services and strategic support to organizations.
In July, AMN Healthcare introduced a new teletherapy platform, Televate. Per the company, it has been designed to increase access to therapy services for students nationwide.
AMN’s Share Price Performance
Shares of the company have lost 50.7% in the past year against the industry’s 7.5% rise and the S&P 500's 30.9% growth.
Image Source: Zacks Investment Research
AMN Healthcare’s Zacks Rank & Key Picks
Currently, AMN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Baxter International Inc. (BAX - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
DaVita, sporting a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 24.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have gained 74.8% compared with the industry’s 31.7% rise in the past year.
Baxter, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10%. BAX’s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.7%.
Baxter has gained 0.7% compared with the industry’s 22.9% rise in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.2%.
Boston Scientific’s shares have rallied 62.4% compared with the industry’s 22.9% rise in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery
AMN Healthcare Services, Inc. (AMN - Free Report) launched an innovative technology suite, WorkWise, last Wednesday. The suite is expected to unify the company’s technologies into one single technology offering.
Per AMN Healthcare, WorkWise has been designed to streamline workforce processes by combining the capabilities of quantifying staffing demand with predictive scheduling, automated workforce management and enhanced clinician engagement using AI technology. The technology suite will likely empower healthcare systems to efficiently source the appropriate talent, while effectively managing costs.
The latest launch is expected to significantly boost AMN Healthcare’s Technology and Workforce Solutions business and solidify its foothold in the healthcare space.
Likely Trend of AMN Stock Following the News
Following the announcement on Oct. 2, shares of the company moved nearly 2.8% south to $38.64 at yesterday’s close.
Historically, the company has gained a high level of synergies from its product launches. Although the latest launch is likely to be beneficial for AMN’s top-line growth going forward, the stock declined overall since the announcement despite a slight gain yesterday.
AMN Healthcare currently has a market capitalization of $1.47 billion. It has an earnings yield of 8.3%, higher than the industry’s 3.6%. In the last reported quarter, AMN delivered an earnings surprise of 30.7%.
Significance of the Launch of AMN Healthcare’s WorkWise
Per AMN Healthcare, WorkWise is completely integrated with healthcare organizations’ internal systems. This is expected to enable hospitals to optimize personnel for any type of job (permanent, per diem, contract), sourcing from internal and external talent, to reduce costs and predict staffing needs with greater precision. The solution will likely leverage automation and data analysis to provide insights and build engaged talent networks for effective workforce management and increased speed-to-fill for staffing needs.
AMN Healthcare’s management believes that WorkWise will be an integrated solution with multiple capabilities that can work together to address complex workforce challenges in the healthcare industry. It is expected to provide a full end-to-end solution for hospitals and healthcare systems, which is built to adapt and evolve with their needs.
Industry Prospects in Favor of AMN
Per a report by Grand View Research, the global healthcare workforce management system market was valued at $1.9 billion in 2023 and is anticipated to witness a CAGR of 13.2% between 2024 and 2030. Factors like the shift toward value-based reimbursements and the increasing adoption of telehealth technologies and AI-driven analytics are likely to drive the market.
Given the market potential, the latest launch will likely provide a significant impetus to AMN Healthcare’s business.
AMN Healthcare’s Notable Launches
In August, AMN Healthcare launched Strategic Partnership Solutions. It aims to transform language access programs in healthcare organizations by providing comprehensive language services and strategic support to organizations.
In July, AMN Healthcare introduced a new teletherapy platform, Televate. Per the company, it has been designed to increase access to therapy services for students nationwide.
AMN’s Share Price Performance
Shares of the company have lost 50.7% in the past year against the industry’s 7.5% rise and the S&P 500's 30.9% growth.
Image Source: Zacks Investment Research
AMN Healthcare’s Zacks Rank & Key Picks
Currently, AMN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Baxter International Inc. (BAX - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
DaVita, sporting a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 24.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have gained 74.8% compared with the industry’s 31.7% rise in the past year.
Baxter, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10%. BAX’s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.7%.
Baxter has gained 0.7% compared with the industry’s 22.9% rise in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.2%.
Boston Scientific’s shares have rallied 62.4% compared with the industry’s 22.9% rise in the past year.